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Introduction
CD8 T cells play a critical role in mediating protection to a variety 
of intracellular pathogens, including Ebola, HIV, tuberculosis, and 
malaria. Replication-defective recombinant adenoviral vectors 
(rAds) are promising candidates for induction of such responses 
in humans, based on their potency, scalable manufacturing capac-
ity, and favorable safety proile. Accordingly, a number of human- 
derived (1–3) and animal-derived (4–7) rAds has been developed for 
use as vaccines against such pathogens. rAd serotype 5 (rAd5) is the 
most potent vector in preclinical and clinical studies but has high 
seroprevalence in human populations due to natural infection (8, 
9), which may limit optimal CD8 immunity. This led to the devel-
opment of alternative rAds based on serotypes with low seropreva-
lence (2, 3, 7), but these vary substantially in their potency and pro-
tective capacity (7–10). Of note, a chimpanzee-derived rAd, chAd3, 
has recently entered accelerated phase I clinical trials for Ebola 
virus infection, after inducing a high level of protection in a preclin-
ical nonhuman primate model (11). Given the potential of rAds to 
induce potent cellular immunity, an understanding of the in vivo 
mechanisms that initiate such responses is critical to facilitate tar-
geted selection of adenovirus serotypes for vector generation and 
to guide further development of these clinically important vaccines.
Prior studies have shown that certain rAds can difer with 
respect to antigen (Ag) expression levels in vivo and their innate 
immunogenicity (3, 12–15) and suggest that these parameters 
afect each other and shape the resulting adaptive immune 
response. Additional in vitro and in vivo studies have examined 
early pathogen-recognition receptor (PRR) signaling and innate 
pathways induced after adenoviral infection or rAd exposure. 
In mice, deiciency of RIG-I–like receptor (RLR) or TLR adaptor 
proteins (mitochondrial antiviral signaling protein [MAVS], mye-
loid diferentiation primary response gene 88 [MyD88], and TIR 
domain–containing adapter-inducing IFN-β [TRIF]) or individ-
ual TLRs can modestly reduce rAd-induced CD8 T cell responses 
(16–20). Adenoviral DNA also potentiates the NALP3-dependent 
inlammasome (21), but mice deicient in a critical component of 
the inlammasome generate normal CD8 T cell immunity after 
rAd5 vaccination (20). Although these studies suggest that PRR 
signaling and innate immune responses promote optimal CD8 T 
cell immunity after rAd vaccination, the in vivo mechanisms that 
inluence induction of CD8 T cell immunity across a broad array 
of rAds are not well deined.
In this study, we assessed the mechanisms that underlie the 
hierarchy of protective CD8 T cell immune responses induced 
by human-, chimpanzee-, and simian-derived rAds (9). We per-
formed correlative analyses of Ag expression, innate immunity, 
CD8 T cell immunity and protection after rAd vaccination. High 
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signaling are the major innate pathways induced by certain rAds, 
which limit Ag expression, but signaling is dispensable for induc-
tion of CD8 T cell memory. Thus, the amount and duration of Ag 
is the best predictor of protective CD8 T cell immunity with rAds, 
while IFN-driven innate responses have a limited role.
Results
Protective CD8 T cell responses after rAd vaccination correlate with 
Ag expression. To deine the potency and protective capacity of 
human-derived rAds, rAd5, rAd28, and rAd35 expressing the SIV-
and prolonged Ag expression was observed with rAd5 and chAd3, 
and this correlated with robust protective CD8 T cell immunity. 
In contrast, strong activation of innate genes, as determined by 
expression proiling in draining lymph nodes (dLNs) after rAd 
vaccination, was observed with other rAds and correlated with 
reduced Ag expression. Moreover, abrogating type I IFN and spe-
ciically stimulator of IFN genes (STING) signaling during rAd 
vaccination increased Ag expression but only accelerated the 
kinetic of CD8 T cell responses and did not alter the magnitude of 
memory responses. These data show that type I IFN and STING 
Figure 1. hierarchy of protective cD8 t cell responses and ag expression after rad vaccination. (a) Frequency of tetramer+ CD8+ T cells in spleens at peak 
(day 23) or once memory CD8+ T cell responses were established (day 70) after vaccination with human-derived rAds. (B) Bacterial load in spleens at day 
108 after challenge with L. monocytogenes expressing Gag. (c) Ag transcript expression in dLNs after vaccination with human-derived rAds at 1 × 109 PU 
or 1 × 108 PU. (D) Tetramer+ CD8+ T cell responses at peak or memory, (e) bacterial load, and (F) Ag expression for chimpanzee-derived rAds. (G) Tetramer+ 
CD8+ T cell responses at peak or once memory CD8+ T cell responses were established, (h) bacterial load, and (i) Ag expression for simian-derived rAds. For 
CD8 T cell responses and bacterial load analysis, mice received all rAds at 1 × 108 PU; rAd35 was administered at both 1 × 109 PU (rAd35hi) and 1 × 108 PU 
(rAd35lo). For Ag expression, mice received rAds at 1 × 109 PU or 1 × 108 PU as indicated. Error bars indicate mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, Mann- 
Whitney test. Dashed lines indicate the limit of detection (LOD). Data represent at least 2 independent experiments (n = 3–6).
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To examine whether Ag dose and duration corresponded with 
induction of protective CD8 T cell immunity, Gag mRNA expres-
sion was assessed over time in the dLNs by quantitative real-time 
PCR analysis (qRT-PCR). rAd5 produced substantially more Gag 
transcript at each time point compared with rAd28 or rAd35, with 
transcript still detected 14 days after vaccination (Figure 1C), and 
lower but persistent expression was also detected with 1 × 107 PU 
rAd5 (K.M. Quinn, unpublished observations). In contrast, no 
transcript could be detected beyond 72 hours after vaccination 
with rAd28 or rAd35 at 1 × 108 PU (Figure 1C). Moreover, rAd35 
produced less transcript than rAd28 at 1 × 108 PU and lost detect-
able expression earlier after vaccination (Figure 1C). Thus, the 
amount and duration of Gag transcript expression correlated with 
the hierarchy of protective CD8 T cell immunity for human rAds.
To extend this analysis, CD8 T cell immunity and transcript 
expression were assessed using rAds from other species, such as 
chimpanzee-derived (chAd3 and chAd63) and simian-derived 
Gag as an Ag were compared. In a previous study, the magnitude, 
quality, and phenotype of CD8 T cell responses induced by rAds 
in C57BL/6 mice were characterized at several diferent doses (9). 
Based on these data, a dose of 1 × 108 particle units (PU) given sub-
cutaneously was chosen to provide a hierarchy of potency when 
memory CD8 T cell responses were established, 70 days after 
vaccination and hereafter referred to as “at memory.” For rAd35, 
which does not elicit detectable responses at this dose (Figure 
1A), mice were vaccinated with 1 × 109 PU (rAd35hi) and 1 × 108 
PU (rAd35lo). Gag-speciic CD8 T cell responses were character-
ized in the spleen, blood, and lung using peptide-MHC I tetramer 
staining. Mice were then challenged with recombinant Listeria 
monocytogenes expressing Gag, as a CD8 T cell–dependent model 
of protection (9, 22). rAd5 induced the most potent and protective 
CD8 T cell responses, followed by rAd28 and rAd35 (Figure 1, A 
and B). rAd35 only induced detectable and protective CD8 T cell 
responses at the 1 × 109 PU dose (Figure 1, A and B).
Figure 2. ag expression and distri-
bution to Dc subsets in vivo after 
rad vaccination. (a) Histograms 
representing EGFP expression after 
rAd vaccination. (B) Number of EGFP+ 
DCs recovered per dLN, MFI of EGFP 
in EGFP+ DCs after rAd vaccination, 
and percentage of CD11c+ DCs that are 
nonviable per dLNs. (c) Number and 
(D) relative proportion of total CD11c+ 
DCs that distribute to each DC subset. 
pDC, plasmacytoid DC; mo.-derived DC, 
monocyte-derived DC. (e) Number and 
(F) relative proportion of EGFP+ CD11c+ 
DCs that distribute to each DC subset. 
Mice received rAd expressing EGFP at 
1 × 1010 PU. ND, no events detected. 
Data are representative of results 
over 3 independent experiments and 
are derived from dLNs pooled from 10 
individual mice.
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rAd35 vaccination (Figure 2, A and B). Similar data were obtained 
at 10 hours after vaccination (K.M. Quinn, unpublished observa-
tions). The median luorescence intensity (MFI) of EGFP+ DCs was 
consistently higher after rAd5 and chAd3 vaccination compared 
with that after chAd63 or rAd35 vaccination, but DC viability was 
equivalent across groups (Figure 2B). This illustrates that rAd5 and 
chAd3 induce higher Ag expression on a per cell basis and suggests 
that the lower number of Ag+ DCs after rAd35 or chAd63 vaccina-
tion is not due to diferential kinetics of Ag expression or cell death 
across the rAds. Collectively, these data demonstrate concordance 
between Gag transcript and Ag protein expression.
The number and relative proportion of each subset among 
total DCs and EGFP+ DCs were then assessed. Among total DCs, 
the number in each subset varied modestly (Figure 2C), but the rel-
ative proportions were comparable across all rAd-vaccinated mice 
(Figure 2D), indicating that DC subsets were similarly recruited to 
the dLNs with all rAds. Among EGFP+ DCs, the number in each 
subset difered substantially (Figure 2E), but the distribution of 
EGFP expression across subsets was similar for all rAds (Figure 
2F). The use of a relatively high dose of rAd may mask diferences 
in tropism among the diferent rAds, so the same analysis was per-
formed with lower doses (5 × 109 PU and 5 × 108 PU). While the 
distribution of Ag with chAd63 at 5 × 109 PU and with rAd35 at 
5 × 108 PU began to difer from higher doses of these vectors, the 
number of EGFP+ DCs acquired was less than the detection limit 
(~500 events) (Supplemental Figure 3). Importantly, the pattern 
of Ag expression remained consistent across rAds and relected 
transcript levels in Figure 1. Overall, DC recruitment to the dLNs 
and Ag distribution across DC subsets was similar, despite poten-
tial tropism efects, and rAds difered primarily in the number of 
Ag-loaded DCs present in the dLNs.
CD8 T cell responses are dependent on cross-presenting DC pop-
ulations. To determine whether speciic DC subsets are required 
for Ag presentation to T cells in vivo, BATF3-deicient (Batf3–/–) 
mice were used. Deiciency of BATF3 prevents the development 
of CD8α+ DCs and langerin+ dDCs (24, 25), which are critical for 
cross-presentation of Ag to CD8 T cells. CD8 T cell responses after 
vaccination with rAd5, rAd35, chAd3, or chAd63 were signiicantly 
lower (~80%) in Batf3–/– mice (Figure 3A); however, Gag-speciic 
(sAd11 and sAd16) vectors. Chimpanzee-derived rAds induced 
lower CD8 T cell responses compared with rAd5 at memory (Fig-
ure 1D) but conferred similar degrees of protection (Figure 1E). At 
a lower dose (1 × 107 PU), chAd3 maintains protection at a similar 
level to rAd5, whereas chAd63 loses protective eicacy (9). Thus, 
chAd3 is more protective than chAd63 and as protective as rAd5 in 
this model. Consistent with these indings, chAd3 and rAd5 pro-
duced similar levels of transcript, while chAd63 lost expression 
rapidly (Figure 1F). Simian-derived rAds also induced signiicantly 
lower CD8 T cell responses and protection compared with rAd5 
once memory CD8+ T cell responses were established (Figure 1, G 
and H). Consistent with this, sAd11 and sAd16 produced markedly 
less transcript than rAd5 at 1 × 109 and 1 × 108 PU (Figure 1I). Of 
note, similar hierarchies for CD8 T cell response magnitude across 
the rAds were observed in blood and lung once memory CD8+ 
T cell responses were established (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI78280DS1). To conclude, the highest levels of sustained Ag 
transcript expression were observed after vaccination with the 
most protective vectors: rAd5 and chAd3.
Ag is expressed in multiple DC subsets with all rAds. While there 
were clear diferences in transcript level across rAds, expression of 
transcript may not relect protein expression. Additionally, difer-
ent adenovirus serotypes can use diferent receptors to enter tar-
get cells (2, 3, 7, 23), which could alter the distribution of Ag across 
DC subsets and afect CD8 T cell immunity. To assess this directly, 
mice were vaccinated with rAd5, rAd35, chAd3, and chAd63 
encoding EGFP. For this analysis, a higher dose of rAd (1 × 1010 
PU) was used to enable detection of a suicient number of events 
by low cytometry to deine Ag distribution to speciic DC subsets. 
At 24 hours after vaccination, EGFP expression was assessed in 6 
major DC subsets in murine skin dLNs (Supplemental Figure 2), 
including lymph node resident (CD8α+ DCs and plasmacytoid 
DCs) and migratory populations (monocyte-derived DCs, lan-
gerin+ and langerin– dermal DCs [dDCs], and Langerhans cells).
Vaccination with rAd5 or chAd3 generated a comparably high 
frequency and number of total CD11c+ DCs expressing EGFP in 
the dLNs (Figure 2, A and B). More modest levels were observed 
with chAd63, and EGFP+ DCs were low to undetectable after 
Figure 3. ag presentation by Dc subsets in vivo after rad vaccination. Frequency of (a) CD8 T cells or (B) CD4 T cells from the spleen that produce IFN, 
IL-2, or TNF in response to AL11 peptide or Gag protein restimulation at 23 days after vaccination in WT or Batf3–/– mice. Mice received rAd expressing  
Gag at 1 × 108 PU for rAd5, chAd3, or chAd63 and 1 × 109 PU for rAd35. Error bars represent mean ± SEM. *P ≤ 0.05, Mann-Whitney test. Data represents  
2 independent experiments (n = 4–5).
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Functional analysis of innate gene activation identiies signii-
cant modulation of IFN signaling-related genes. To deine difer-
ences in innate gene activation between rAds that could lead to 
diferent functional outcomes, ingenuity pathway analysis was 
used to identify known innate pathways that are enriched within 
the set of rAd-regulated transcripts. In the top 15 pathways iden-
tiied, IFN signaling was among the most signiicant (Figure 5A) 
and included alterations in levels of Ifng, Ifnb, the IFN-γ receptor 
subunit 1 (Ifngr1), IFN regulatory factor 9 (Irf9), and many other 
transcripts (Figure 5B). Some IFN-associated transcripts, such as 
Irf9, were uniformly modulated in response to all rAds, whereas 
other transcripts, such as Ifng, Ifnb, and Ifngr1, were diferentially 
regulated across rAds (Figure 5B).
As an alternative approach, gene coexpression modules were 
identiied. These modules are groups of genes that exhibit con-
cordant regulation across rAds and time points and ofer an alter-
CD4 T cell responses were comparable to those of WT mice (Fig-
ure 3B). Thus, CD8α+ DCs and/or langerin+ dDCs are essential for 
optimal CD8 T cell responses after vaccination for all rAds tested.
rAds induce robust local innate responses in the dLNs. After dein-
ing Ag dose, duration, and localization, we next assessed innate 
immune responses after rAd vaccination. Since rAds may engage 
multiple innate signaling pathways, gene expression proiling of the 
dLNs was performed to provide a global and unbiased characteri-
zation of innate immunity at the site of T cell priming in vivo (26, 
27). A total of 3,888 diferentially regulated transcripts responsive 
to rAd28, rAd35, chAd3, chAd63, sAd11, or sAd16 were identiied 
at 8, 24, or 72 hours after vaccination (Figure 4A and Supplemen-
tal Table 1). Principal components analysis revealed that the rAd5, 
sAd16, and chAd3 vectors and rAd28, rAd35hi, sAd11, and chAd63 
vectors grouped together at 8 hours through to 72 hours, with the 
clearest distinction between these 2 groups at 24 hours (Figure 4B).
Figure 4. characterization of innate gene activation in vivo after rad vaccination. (a) Heat map analysis of all genes that were signiicantly upregulated 
or downregulated in the dLNs at 8, 24, and 72 hours after vaccination with each rAd. Colors indicate scaled fold changes (magenta, upregulated; white, no 
change; cyan, downregulated) compared with the average response in mice vaccinated with PBS control. (B) Principal components analysis of gene expres-
sion changes at 8, 24, and 72 hours after rAd vaccination. Grouping of rAd5, sAd16, and chAd3 and grouping of rAd28, rAd35, sAd11, and chAd63 at 24 hours 
is indicated by the light gray ovals.
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native unbiased approach to identify pathways induced by rAd 
vaccination. Fourteen modules were identiied and annotated 
by functional enrichment analysis (Figure 6 and Supplemental 
Tables 2 and 3). Additionally, rAd regulation of previously deined 
coexpression modules (refs. 28, 29, and Supplemental Table 3) 
was investigated. The most signiicantly diferentially regulated 
modules from both our study and other studies contained IFNs 
and IFN-stimulated genes (ISGs) (modules C3 and C2 from our 
study; module M1.2/1.3/5.12 from Obermoser et al., ref. 28; and 
module 52 from Jojic et al., ref. 29). Thus, both ingenuity pathway 
analysis and an unbiased module-based analysis identiied IFN 
signaling as the major innate pathway triggered by rAds.
Gene expression kinetics involved robust upregulation of 
type I and type II IFNs (module C3) early after vaccination at 
8 hours, followed by the induction of ISGs by 24 hours (modules 
C2, M1.2/1.3/5.12, and 52) and near complete resolution by 72 
hours. This occurred alongside complex patterns of gene down-
regulation. Radar plots of module expression and representative 
genes illustrate these dynamics (Figure 7A). Generally, the rAds 
regulate a common set of modules and genes but to diferent 
degrees. They difered substantially in the magnitude of IFN-
driven innate gene induction, with the most protective vectors, 
rAd5 and chAd3, inducing transcription of such genes to the weak-
est extent compared with other vectors (Figure 7A).
For protein-level validation of the transcriptional patterns, 
serum levels of IFN-α and IP-10 were measured, representing a 
type I IFN from module C3 and an ISG from module C2, respec-
tively. Vaccination with rAd28, rAd35, sAd11, or chAd63 resulted 
Figure 5. ingenuity pathway analysis of innate gene activation in vivo after rad vaccination. (a) Analysis of canonical pathway enrichment in genes 
diferentially expressed 8 hours after rAd vaccination. The left axis (bar plots) shows percentage of genes annotated to a given canonical pathway that 
were upregulated (magenta) or downregulated (cyan) in dLNs at 8 hours after rAd vaccination. The right axis (line graph) shows log
10
 probability (P value) 
that an equivalent number of genes in the indicated pathways could be obtained by randomly selecting gene groups of the same size. Results are shown 
for the top 15 pathways with P < 1 × 10–4. Numbers above bars indicate the number of genes included each pathway. (B) Fold change (log
2
) in expression of 
type I and type II IFN signaling transcripts Ifng, Ifnb, Ifngr1, and Irf9 over time after vaccination with each rAd compared with the PBS control. Error bars 
represent mean ± SEM (n = 4–8).
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in high serum levels of IFN-α and IP-10 at 10 hours after vaccina-
tion, but there was no detectable induction of these cytokines after 
either rAd5 or chAd3 vaccination (Figure 7, B and C), conirming 
the relative magnitude of IFN responses across the diferent rAds.
Last, rAd-regulated transcriptional responses were interro-
gated for diferential dynamics. From the 3,888 rAd-regulated 
genes (Figure 4A and Supplemental Table 1), 526 upregulated and 
758 downregulated genes were identiied that were responsive to all 
rAds but that showed diferences in terms of the irst time point and/
or persistence of induction or repression (Supplemental Table 4). 
Sets of genes showing similar patterns of diferential dynamics 
among the rAds were overrepresented for several functional anno-
tations (refs. 28, 30, and Supplemental Table 5). IFN response 
genes exhibited robust induction by all rAds at 8 and 24 hours but 
showed striking diferences in persistence at 72 hours, with sAd16 
responses being particularly transient, followed by those of chAd3 
and rAd5. A subset of killer cell lectin-like receptor subfamily A 
(KLRA) genes was identiied that was markedly and preferen-
tially induced by rAd5 or chAd3 at 24 hours and later induced by 
all vectors at 72 hours. These results demonstrate that rAds difer 
in terms of gene regulation kinetics, although the diferences in 
terms of response magnitudes are more striking.
Local and peripheral responses relect distinct 
biological processes but preserve innate hierarchy. 
Currently, most human studies proiling innate 
activation after vaccination in vivo, including 
previous analysis of responses to the Merck 
rAd5 (MRKAd5), assess transcriptional changes 
in whole blood or peripheral blood mononu-
clear cells (PBMCs), as these are the most 
accessible tissue for analysis in human subjects 
(26, 28, 31, 32). Such analyses have provided 
critical insights, linking systemic innate acti-
vation to vaccine-induced responses, but how 
the systemic responses relate to innate gene 
activation at local sites of T cell priming has 
not been assessed directly. To this end, rAd- 
induced innate immune responses in vivo in 
dLNs (all rAds) and PBMCs (rAd5 and rAd28) 
were compared and integrated with human in 
vivo responses to MRKAd5 (26). As systemic 
human responses to MRKAd5 peaked at 24 hours 
(26), the analysis focused on this time point.
Signiicant overlap between the 2 compart-
ments was observed. Between the 2,133 and 813 
genes upregulated in dLNs and PBMCs, respec-
tively, there was an intersection of 262 genes (P = 3 × 10–47). 
Between the 3,781 and 818 genes downregulated in dLNs and 
PBMCs, respectively, there was an intersection of 285 genes 
(P = 3 × 10–14). Unexpectedly, there also was appreciable overlap 
among genes upregulated in dLNs and downregulated in PBMCs 
(77 genes) and genes downregulated in dLNs and upregulated in 
PBMCs (194 genes). In this manner, 4 clusters of genes based on 
concordant (groups I and II) or discordant (groups III and IV) reg-
ulation in the 2 tissues were deined (Figure 8A).
Concordantly upregulated genes (group I) were most strongly 
enriched for IFN-related modules (Table 1; M1.2/3.4/5.12; ref. 
28), with nearly every gene from groups I to IV with this anno-
tation falling into group I (Figure 8B). Of note, both group I and 
group III were strongly enriched for inlammatory module genes 
(Table 1; M3.2/4.13/4.2/4.6/5.1/5.7/7.1; ref. 28). While nearly 
every gene from groups I to IV with this annotation was upregu-
lated in the PBMCs, they were split evenly between being upreg-
ulated and downregulated in dLNs (Figure 8B). These data high-
light a complex relationship between vaccine-induced innate 
immune responses that are measured locally (in the dLNs, at 
the site of Ag presentation) and systemically (in PBMCs). While 
peripheral induction of IFN responses relects induction of 
Figure 6. Deinition of modules responsive to rad 
vaccination. Heat map analysis and coexpression 
clustering of genes that were coordinately upregulated 
or downregulated at 8, 24, and 72 hours after vaccina-
tion with each rAd. Fourteen modules were delineated, 
and genes comprising each module are described in 
Supplemental Tables 2 and 3. Colors indicate scaled fold 
changes (magenta, upregulated; black, no change; cyan, 
downregulated) compared with the average response in 
mice vaccinated with PBS control.
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the 2 compartments for rAd5 and rAd28. While responses to the 2 
vectors correlated in both tissues (with correlation coeicients of 
RdLN = 0.95, RPBMC = 0.86), responses to rAd5 were nearly uniformly 
weaker than responses to rAd28 in both dLNs (P = 1.5 × 10–9) and 
PBMCs (P = 2 × 10–20) (Figure 8, C and D, in which most points are 
below the red line). Even though transcriptional analysis of dLNs 
and PBMCs detects a mixture of overlapping and distinct biological 
processes, these results demonstrate that proiles from both tissues 
can be used to comparably rank the innate stimulatory potency of 
diferent rAds, although IFN responses may be more pronounced 
in the local environment.
The magnitude of innate responses correlate inversely with Ag 
expression. We then analyzed whether expression of speciic genes 
or modules correlated with speciic outcomes, such as Ag expres-
sion, magnitude of CD8 T cell immunity, and protection. Although 
a number of associations between innate and adaptive immunity 
were detected, the most striking correlation was induction of mod-
ules C2 and C3 at 24 hours after vaccination and Ag expression at 
72 hours after vaccination (r < –0.75, P < 1 × 10–28, ANOVA; Sup-
such responses in the dLNs, induction of inlammatory genes in 
PBMCs may actually be opposite of local responses.
Signiicant overrepresentation of cell-type associated mod-
ules was observed in discordantly regulated groups (III and IV). 
Genes upregulated in PBMCs but downregulated in dLNs (group 
III) were enriched for associations with monocytes (Table 1), 
including colony-stimulating factor 1 receptor (Csf1r) and Ccr2 
(Figure 8C), consistent with decreased proportions of monocytes 
found in the dLNs after rAd vaccination at 24 hours (Supplemen-
tal Figure 4A). Genes downregulated in PBMCs but upregulated 
in dLNs (group IV) were enriched for associations with B cells 
(Table 1), including Cd19 and Cxcr5 (Figure 8C), consistent with 
increased proportions of B cells after rAd vaccination (Supple-
mental Figure 4A). This illustrates that a discordant transcrip-
tional response can result from reciprocal traicking between 2 
compartments, with dilution of monocytes but recruitment of 
B cells to the dLNs after rAd vaccination.
Finally, the hierarchy of murine responses to rAds for the 547 
concordantly regulated genes (groups I and II) was compared in 
Figure 7. Module analysis over time after rad vaccination. (a) Radar plots comparing the kinetics of innate gene activation: either upregulation or down-
regulation of each module or individual genes from modules C2 and C3 relative to the PBS control with each rAd at 8, 24, and 72 hours after vaccination. 
Axes represent (top) maximum = +4, minimum = –4, circles = +4 (outside), +3, +2, +1, 0 (gray circle), –1, –2, –3, and –4 or (bottom) maximum = +8, mini-
mum = –1, circles = +8 (outside), +7, +6, +5, +4, +3, +2, +1, 0 (gray circle), and –1. (B and c) Amount detected in serum of (B) IFN-α at 10 hours and (c) IP-10 
at 24 hours after vaccination with rAds. On radar plots, each plot partition represents ± 1 log
2
 fold change relative to PBS. Error bars represent mean ± SEM. 
*P ≤ 0.05, for each rAd compared with PBS, Mann-Whitney test. Data in B and c represent 2 independent experiments (n = 4–6).
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and B, and refs. 33, 34). Persistent Ag expression also correlated 
inversely with module C3, containing the type I IFN genes Ifna1, 
Ifna2, Ifna12, and Ifnb1 (Figure 9, A and B), and with the IFN- 
related M1.2/3.4/5.12 and 52 modules deined by other studies 
(Supplemental Table 6). Thus, more robust upregulation of IFN-
driven modules at 24 hours was associated with impaired Ag 
plemental Table 6). Persistent Ag expression correlated inversely 
with module C2, consistent with antiviral mechanisms that are 
controlled by many ISGs, such as 2′-5′-oligoadenylate synthetase 
1a, 2, or 4, which activates RNase L to eliminate viral transcripts, 
and eukaryotic translation initiation factor-α kinase 2 (EIFAK2; 
also known as PKR), which inhibits protein synthesis (Figure 9, A 
Figure 8. comparison of local (dlNs) and systemic (PBMcs) innate gene activation. (a) Heat map of 818 genes signiicantly responsive to rAd vaccination 
in dLNs or PBMCs, for mice or humans, at 24 hours after vaccination. Genes are clustered into concordantly (group I, 262 genes; group II, 285 genes) or 
discordantly (group III, 194 genes; group IV, 77 genes) regulated genes. Colors indicate scaled fold changes (magenta, upregulated; white, no change; cyan, 
downregulated) for the mean – SEM, mean, and mean + SEM response compared with the average response to PBS control (mice) or levels before vaccina-
tion. (B) Median expression fold changes across all vectors and species in dLNs plotted against the median expression fold changes in PBMCs for all genes 
comprising the IFN response module or inlammation module. Each point represents a unique gene. (c) Fold changes in gene expression as compared with 
PBS control mice for select genes that are discordantly (Csf1r and Ccr2 or Cd19 and Cxcr5) or concordantly (Oas2 and Eif2ak2) regulated. (D) Average gene 
expression fold changes (compared with PBS) induced by rAd5 are plotted against fold changes induced by rAd28 in dLNs or PBMC samples for all genes 
that were found to be concordantly regulated between the 2 tissues. Each point represents a unique gene. The red line indicates y = x.
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of the NK cell compartment. Accordingly, the impact of 
NK cells on induction of CD8 T cell immunity with rAd5 
and rAd35 vaccination was assessed through depletion 
of NK1.1+ cells (Supplemental Figure 4B), but this did not 
afect CD8 T cell responses (Supplemental Figure 4C). 
Thus, there is highly speciic regulation of NK-associ-
ated genes, but the functional implication of this obser-
vation is unclear.
Exogenous induction of type I IFN by poly I:C adminis-
tration limits Ag expression and CD8 T cell immunity. Due 
to the inverse correlation between type I IFN induction 
and Ag expression following rAd vaccination, we deter-
mined whether type I IFN directly afects Ag expression 
and CD8 T immunity. Since rAd5 had the lowest induc-
tion of type I IFN and highest expression of Ag, mice were 
vaccinated with rAd5 alone or received codelivery of rAd5 
with chAd63 containing an irrelevant Ag (HIV-Env) or the 
adjuvant polyinosinic/polycytidylic acid I:C (poly I:C), 
both potent inducers of type I IFN in vivo (Figure 10A). 
Codelivery of chAd63 or poly I:C signiicantly reduced 
Gag transcript expression (Figure 10B). Codelivery of poly 
I:C also reduced the number of total DCs in dLNs (Figure 
10C) and their MFI for EGFP (Figure 10D), while there 
was no change in the frequency of nonviable cells (Figure 
10E). Thus, exogenous induction of type I IFN by code-
livery of poly I:C with rAd5 decreased DC recruitment 
and Ag expression on a per cell basis, leading to fewer 
Ag-loaded DCs in the dLNs (Figure 10F) and reducing the 
peak CD8 T cell response (Figure 10G).
Abrogation of type I IFN signaling increases Ag expression and 
accelerates induction of CD8 T cell immunity. To further examine 
how endogenous type I IFN inluences Ag expression and CD8 
T cell immunity, mice deicient in IFN-αR1 (Ifnabr–/– mice) (36), 
a receptor subunit essential for type I IFN signaling, were vacci-
nated with rAd5 or chAd63, since these rAds showed the largest 
diference in the magnitude of their innate immune response. 
Activation of innate modules and genes was markedly higher after 
chAd63 vaccination compared with that after rAd5 vaccination in 
WT mice (Figure 11A). Such responses were strikingly reduced in 
Ifnabr–/– mice relative to those in WT mice after chAd63 vaccina-
tion, although low-level residual induction of individual IFN genes 
and ISGs in modules C2 and C3 was still evident relative to the 
PBS control (Figure 11A). Expression of Gag transcript was similar 
between WT and Ifnabr–/– mice after rAd5 vaccination, as expected 
based on the limited induction of IFNs and ISGs by rAd5, but 
Ifnabr–/– mice produced signiicantly more transcript than WT 
mice after chAd63 vaccination (Figure 11B). A higher number of 
total DCs in the dLNs (Figure 11C) with higher EGFP MFI (Fig-
ure 11D) was observed in dLNs from Ifnabr–/– mice, while the fre-
quency of nonviable cells was similar in both strains (Figure 11E), 
again suggesting that type I IFN limits DC recruitment and Ag 
expression, without afecting cell viability. Consistent with this, 
Ifnabr–/– mice had consistently higher numbers of EGFP+ DCs in 
the dLNs after chAd63 vaccination (Figure 11F).
In concordance with the ability of rAds to induce type I IFN in 
vivo, CD8 T cell responses induced by rAd5 were not signiicantly 
diferent between WT and Ifnabr–/– mice but were signiicantly 
expression at 72 hours after rAd vaccination, suggesting that IFN-
driven signaling reduced Ag expression.
The full complement of innate immune responses associated 
with diferences in rAd Ag expression was then determined by 
integrating the Ag expression data with all genes on the microar-
rays. This analysis identiied 4,285 genes exhibiting signiicant 
(false discovery rate [FDR] <1%) associations with Ag expres-
sion (Supplemental Table 7). Module (28, 30) and immunologi-
cally focused MSIGDB (35) enrichment analyses identiied 773 
modules and gene sets that were signiicantly (FDR <1%) over-
represented in genes positively or negatively associated with Ag 
expression (Supplemental Table 8). The top 10 enriched modules 
and gene sets (FDR = 10–61 to 10–38) involve negative associations 
between Ag expression and IFN response or responses to viruses 
or viral vectors. While this analysis revealed that many biological 
processes are associated with Ag expression, it showed that the 
negative association with the IFN response is the strongest.
Integrating the 4,285 genes associated with Ag expression 
(Supplemental Table 7) with the 3,888 diferentially expressed 
genes (Figure 4A and Supplemental Table 1) revealed that a small 
group of rAd-induced genes were positively correlated with Ag 
expression. Over half of these genes were associated with NK 
cell functions, including KLRA genes Klra7 (Figure 9C); Klra4, 
Klra15, Klra16, and Klra23 (D.E. Zak, unpublished observations); 
Klrd1 (Figure 9C); and granzyme M (D.E. Zak, unpublished obser-
vations). This suggests that high and persistent Ag expression by 
rAd5 and chAd3 may not only result from attenuated IFN induc-
tion by these vectors but also from speciic and positive regulation 
table 1. Gene enrichment analysis for clusters defined by tissue-specific 
expression
Group Module No. of  
genes
FDR (vs.  
genome)
FDR (vs.  
clusters)
I IFN 54 2.8 E-69 2.6 E-25
Antiviral IFN signature 11 7.9 E-13 1.3 E-04
Innate antiviral response 8 1.8 E-11 3.5 E-04
Type I IFN response 8 5.6 E-11 3.5 E-04
Viral sensing and immunity: IRF2 targets 11 1.2 E-12 3.6 E-04
Inflammation 42 5.8 E-11 9.1 E-04
Enriched in activated DCs 10 4.1 E-08 2.1 E-03
Activated DCs 6 3.4 E-07 9.9 E-03
II T cells 13 1.9 E-07 3.2 E-03
III Enriched in monocytes 33 4.4 E-24 5.3 E-08
Inflammation 43 1.4 E-15 3.9 E-07
Cell cycle and transcription 25 2.4 E-12 1.3 E-05
Apoptosis/survival 9 1.1 E-07 1.3 E-04
Monocytes 10 8.5 E-09 3.5 E-04
IV Enriched in B cells 7 1.4 E-06 3.6 E-04
Cell cycle 9 2.8 E-03 5.0 E-04
Enriched in T cells 5 3.6 E-04 8.6 E-04
Each cluster (groups I–IV) was defined with regard to innate modules published by 
Obermoser et al. (28) and Li et al. (30), with FDRs indicated as compared with the 
whole genome or all other clusters. Data for IFN and inflammation modules correlate 
with those for these modules shown in Figure 8B.
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vated by cytosolic DNA via the action of DNA sensors, such as 
cyclic GMP-AMP synthase (37–39), or directly activated by bacte-
rially generated cyclic dinucleotides (39, 40) and may detect viral 
fusion events (41). Recent in vitro studies have shown that STING 
activates innate pathways after adenoviral infection (42, 43) and 
mediates a key innate signaling pathway for sensing a variety of 
viruses with dsDNA or RNA genomes (44).
Mice were vaccinated with rAd5 or chAd63 at a low dose 
(3 × 107 PU) to focus on innate regulation of CD8 T cell responses 
in the context of more limiting Ag, as high doses of rAds can mask 
the inluence of innate pathways in mice (18, 19). Mavs–/– mice did 
not difer signiicantly from WT mice in terms of IP-10 production 
(Figure 12A), Ag expression (Figure 12B), or CD8 T cell response 
higher in Ifnabr–/– mice early (up to day 21) after chAd63 vaccina-
tion (day 14; Figure 11G). Of note, such responses were compara-
ble at day 28 and once memory responses were established (day 
56) (Figure 11G). These data show that type I IFN signaling with 
rAds reduces Ag expression and alters the kinetics of CD8 T cell 
immunity but is dispensable for CD8 T cell memory.
Signaling through distinct PRRs can promote or suppress adap-
tive immunity after rAd vaccination. To identify speciic PRRs 
potentially responsible for the diferences in rAd-induced innate 
immune responses and type I IFN induction, mice deicient in 
2 major adaptor proteins, MAVS and STING, were used. MAVS 
mediates RLR signaling, whereas STING localizes to the mem-
brane of the endoplasmic reticulum, where it is indirectly acti-
Figure 9. correlation of ag expression with innate gene expression. (a) Heat map representation of genes from module C2 and C3 that exhibit diferential 
regulation at 24 hours that is signiicantly negatively associated with Ag expression at 72 hours after rAd vaccination in the dLNs. Colors indicate scaled 
fold changes (magenta, upregulated; white, no change; cyan, downregulated) for the mean – SEM, mean, and mean ± SEM response compared with the 
average response in mice vaccinated with PBS control. (B) Scatter plots of negative correlations between Ag expression at 72 hours and module C2 or 
genes derived from C2, such as Eif2ak2, and with module C3 or genes derived from C3, such as Ifna1, with gene expression assessed at 24 hours. (c) Scatter 
plots of positive correlations between Ag expression at 72 hours and NK-related gene expression (Klra7 and Klrd1) at 24 hours. Red shading bounded by 
black lines represents 99% conidence intervals (from stratiied bootstrap resampling of spline its between innate gene expression and Ag), colored lines 
in x and y planes are SEM for each vaccine group (for genes or Ag), and shading in gray scale represents the scatter plot for combining all possible innate 
data with all possible Ag data for each vector.
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The kinetics of primary CD8 T cell responses were acceler-
ated after chAd63 vaccination in STING gt/gt mice (Figure 12G), 
similar to that observed after vaccination of Ifnabr–/– mice (Figure 
11G). However, STING was dispensable for early rAd5-induced 
(Figure 12G) and rAd28-induced (Supplemental Figure 6) CD8 
T cell responses, highlighting that STING’s impact can difer 
across rAds. STING was also dispensable for CD8 T cell memory 
induction (Figure 12G), protective capacity (Supplemental Figure 
7, A–D), and expansion in response to secondary Ag using a pep-
tide subunit vaccine to boost (Supplemental Figure 7E), providing 
additional evidence that the functional potential of such cells is 
independent of STING signaling.
Finally, we directly compared gene expression in WT, Ifnabr–/–, 
and STING gt/gt mice after rAd vaccination to identify STING-inde-
pendent IFN-driven pathways. Unexpectedly, the proile of STING 
magnitude (Figure 12C) with either rAd5 or chAd63. In contrast, 
IP-10 production was abrogated after chAd63 vaccination of mice 
with a missense inactivating point mutation in STING (Tmem173gt/gt 
mice, herein referred to as STING gt/gt mice) (ref. 45 and Figure 
12D), and Ag expression was signiicantly higher as compared with 
that in WT mice after vaccination with chAd63 (Figure 12E). Sur-
prisingly, serum levels of IP-10 were also signiicantly lower and 
Ag expression was signiicantly higher in STING gt/gt mice after 
rAd5 vaccination (Figure 12, D and E). This may be due to the 
lower baseline IP-10 levels in naive STING gt/gt mice (Figure 12F), 
which may render such mice more permissive for Ag expression 
with viral vectors in general. IP-10 production was also abrogated 
in STING gt/gt mice after rAd28 and rAd35 vaccination (Supple-
mental Figure 5), demonstrating that a requirement for STING in 
innate sensing is generalizable to other rAds.
Figure 10. efect of enhancing type i iFN signaling on ag expression and cD8 t cell immunity. (a) Radar plots of modules and individual genes within 
modules C2 and C3 at 24 hours after vaccination with rAd5, chAd63, or poly I:C. Axes represent (left) maximum = +4, minimum = –4, circles = +4 (outside), 
+3, +2, +1, 0 (gray circle), –1, –2, –3, and –4 or (right) maximum = +8, minimum = –1, circles = +8 (outside), +7, +6, +5, +4, +3, +2, +1, 0 (gray circle), and –1 log
2
 
fold change relative to PBS. (B) Ag expression at 40 hours after vaccination with 1 × 107 PU rAd5 with or without 1 × 108 PU chAd63 or 50 μg poly I:C. (c) The 
number of total CD11c+ DCs, (D) the MFI of EGFP in EGFP+ DCs, (e) the frequency of nonviable CD11c+ DCs, and (F) the number of live EGFP+ CD11c+ DCs per 
dLN at 24 hours after vaccination with 5 × 108 PU rAd5-EGFP with or without 50 μg poly I:C. (G) Tetramer+ CD8+ T cell responses at day 28 after vaccination 
with 1 × 107 PU rAd5 with or without 50 μg poly I:C. Error bars represent mean ± SEM. **P ≤ 0.01, Mann-Whitney test. The dashed line indicates the LOD. 
Data represent (B and G) 3 independent experiments with n = 3–6 or (c–F) 5 to 10 pooled dLNs per group.
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important aspect of optimizing immunity and protection with rAds 
is the striking variability in potency among diferent serotypes. 
The data presented here, showing that CD8 T cell immunity with 
a variety of human, chimpanzee, and simian rAds is correlated 
with the amount and duration of Ag expression, provide a mech-
anistic basis for understanding diferences among the serotypes. 
Remarkably, there was an inverse correlation between the amount 
of Ag expressed and the magnitude of innate immunity and, spe-
ciically, pathways driven by type I IFN and STING signaling.
This study used a systems biology approach to assess innate 
mechanisms of rAd immunogenicity in the dLNs, which demon-
strated that rAds difer profoundly in terms of the innate response 
magnitude, dynamics, and pathways triggered. The dLNs are 
generally not accessible for proiling in humans, in which similar 
analyses during clinical vaccine trials have relied on proiling of 
PBMCs (26, 28, 31, 32). To put the current study in the context of 
this growing body of work, murine dLN responses were integrated 
with in vivo PBMC responses measured after vaccination with 
rAds in mice and humans (26). The induction of IFN responses 
and the hierarchy of innate stimulation among rAds were found 
to be consistent between dLNs and the periphery, but impor-
tant diferences were also observed, particularly in transcripts 
gt/gt mice for all IFN-driven modules and the individual genes 
identiied by module-based analysis was indistinguishable from 
that of mice administered PBS control (Figure 12H). This con-
trasted with the proile of Ifnabr–/– mice, in which innate immune 
responses after vaccination with rAds were not completely sup-
pressed, resulting in residual gene expression (Figure 12I). STING 
gt/gt mice therefore have a more profound deiciency in rAd-in-
duced innate immune responses than Ifnabr–/– mice. Nevertheless, 
STING gt/gt mice were capable of type I IFN production through 
STING-independent innate pathways. Bypassing STING signaling 
through coadministration of poly I:C with chAd63 induced robust 
IP-10 production in STING gt/gt mice (Figure 12J) and limited the 
peak CD8 T cell responses in STING gt/gt mice (Figure 12K). Col-
lectively, these data suggest that STING is a proximal and dominant 
innate sensor of rAds in vivo and acts upstream of IFN production.
Discussion
Vaccines that induce robust and durable CD8 T cells will be crit-
ical for preventative and therapeutic vaccines against a range of 
infections and tumors. In this regard, due to their safety proile, 
potency, manufacturing scalability, and number of diferent sero-
types, rAds provide a useful platform for clinical translation. An 
Figure 11. efect of abrogating type i iFN signaling on ag expression and cD8 t cell immunity. (a) Radar plots of modules and individual genes within 
modules C2 and C3 24 hours after vaccination of WT or Ifnabr–/– mice with rAd5 or chAd63. Axes represent (left) maximum = +4, minimum = –2, circles = 
+4 (outside), +3, +2, +1, 0 (gray circle), –1 and –2, or (right) maximum = +8, minimum = –1, circles = +8 (outside), +7, +6, +5, +4, +3, +2, +1, 0 (gray circle), and 
–1 log
2
 fold change relative to PBS. (B) Ag expression at 40 hours after vaccination of WT or Ifnabr–/– mice with 1 × 108 PU rAd5 or chAd63. (c) The number 
of total CD11c+ DCs per dLN, (D) the MFI of EGFP in EGFP+ DCs, (e) the frequency of nonviable CD11c+ DCs, and (F) the number of live EGFP+ CD11c+ DCs at 
24 hours after vaccination of WT or Ifnabr–/– mice with 1 × 1010 PU of chAd63-EGFP. (G) Tetramer+ CD8+ T cell responses after vaccination of WT or Ifnabr–/– 
mice with 3 × 107 PU rAd5 or chAd63. Error bars represent mean ± SEM. **P ≤ 0.01, Mann-Whitney test. The dashed line indicates the LOD. Data represent 
(B and G) 3 independent experiments with n = 3–6 or (c–F) 5 to 10 pooled dLNs per group.
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The systems biology approach was complemented by an 
assessment of the role of DC subsets in CD8 T cell responses. 
Indeed prior studies have shown that rAd-transfected hematopoi-
etic and nonhematopoietic cells control expansion and mainte-
nance of CD8 T cells, respectively, after rAd5 vaccination (20, 46). 
Here, we show that Batf3 expression, which is required for gen-
eration of CD8α+ DCs and langerin+ dDCs (24, 25), is critical for 
associated with speciic cell types. This illustrates that reciprocal 
cellular traicking, in the case of this study with monocytes and 
B cells, can greatly afect the gene expression proile of diferent 
tissues. Given the similarities and diferences observed across the 
2 compartments, the results highlight key considerations for the 
mechanistic interpretation of peripheral transcriptomes deined 
in human studies.
Figure 12. efect of PRR signaling on innate immunity, ag expression, and cD8 t cell responses. (a) IP-10 production in serum (14 hours), (B) Ag expres-
sion in the dLNs (40 hours), and (c) tetramer+ CD8+ T cell responses in peripheral blood (28 days) after vaccination of WT or Mavs–/– mice with 3 × 107 PU 
of rAd5 or chAd63. (D) IP-10 and (e) Ag expression after vaccination of WT or STING gt/gt mice. (F) IP-10 in naive serum. (G) CD8+ T cell responses after 
vaccination of WT or STING gt/gt mice. (h) Radar plots of modules and individual genes at 24 hours after vaccination of WT mice with rAd5 or WT and 
STING gt/gt mice with chAd63. Axes represent (left) maximum = +4, minimum = –2, circles = +4 (outside), +3, +2, +1, 0 (gray circle), –1 and –2 or (right) 
maximum = +8, minimum = –1, circles = +8 (outside), +7, +6, +5, +4, +3, +2, +1, 0 (gray circle), and –1 log
2
 fold change relative to PBS. (i) Heat map analysis 
of IFN-driven genes in Ifnabr–/– and STING gt/gt mice after rAd5 or chAd63 vaccination. Colors indicate scaled fold changes (magenta, upregulated; black, 
no change; cyan, downregulated) compared with the average response in PBS control. (J) IP-10 and (K) CD8+ T cell responses after chAd63 vaccination 
with or without 50 μg poly I:C. Error bars represent mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, Mann-Whitney test. Dashed lines indicate LOD. Data represent 3 
independent experiments (n = 3–6).
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vaccinia virus (52, 53). During vaccination, the presence of type I 
IFN typically enhances induction of CD8 T cell responses, such 
as with the modiied vaccinia virus Ankara, an attenuated viral 
vaccine (56), and with protein subunit vaccination, in which adju-
vants that induce robust IFN increase Ag uptake, promote cross- 
presentation, and thereby enhance T cell immunity (22, 57, 58). In 
contrast, the data presented herein demonstrate that type I IFN 
signaling limits Ag expression with rAd vaccination and can limit 
the initial expansion of CD8 T cell responses. These data suggest 
that rAd vaccination mimics natural viral infection, in which IFN-
driven antiviral mechanisms limit viral replication through sup-
pression of transcription or translation or through active mecha-
nisms of elimination, such as NK-mediated killing. Other studies 
have shown that in vitro infection of human DCs with rAd28 and 
rAd35, but not rAd5, leads to increased susceptibility of those DCs 
to NK cell–mediated killing and loss of transgene expression (59). 
We observed diferential expression of NK-related markers in the 
dLNs after rAd vaccination, but depletion of NK cells during rAd5 
and rAd35 vaccination had no efect on CD8 T cell responses. Fur-
thermore, we show that robust induction of type I IFN production 
suppresses Ag translation in DCs rather than afecting DC viabil-
ity after rAd vaccination. Thus, while type I IFN signaling is not 
required for induction of CD8 T cell immunity with rAds, the role 
of NK cells in vivo remains unclear.
STING-mediated signaling has also recently been shown to 
afect induction of CD8 T cell responses to infection. STING gt/gt 
mice challenged with L. monocytogenes exhibited similar primary 
but augmented secondary CD8 T cell responses to Ag stimula-
tion (60). We did not observe such a diference with secondary Ag 
exposure after rAd vaccination, either with live infection or with a 
peptide/poly I:C boost. We also show that STING signaling had a 
striking efect on Ag load during priming of rAd vaccination, but 
this difers from the L. monocytogenes infection model, in which 
no efect on pathogen load is seen (45). STING may be activated 
directly by cyclic dinucleotides with cytosolic bacterial infection 
(45) but requires the action of a DNA sensor for viral DNA (39), 
with both mechanisms having potentially diferent thresholds for 
activation, highlighting that STING may have subtly diferent roles 
in bacterial and viral models. Diferences in the impact of STING 
signaling on induction of CD8 T cell immunity between listerial 
infection and rAd vaccination settings may relect the threshold 
of the innate response induced in combination with the amount, 
kinetic, and localization of Ag produced in each model.
In conclusion, the data presented here provide fundamental 
criteria for downselection from the array of available adenoviral 
serotypes to clinical development of rAd vaccines. Historically, 
selection for rAds has been based on a variety of factors, which 
include potency in preclinical animal models, low seroprevalence 
in humans (2, 3, 7, 8), and strong induction of innate cytokine in in 
vitro culture conditions (3). Indeed, human in vitro studies show 
that type I IFN production by DCs is strikingly higher with rAd35 
than rAd5 (61) and rAd35 also induces higher levels of innate serum 
cytokines than rAd5 in nonhuman primates (15). However, in all 
species tested, rAd5 induces T cell responses of signiicantly greater 
magnitude compared with rAd35. Here, we show that robust in 
vitro and in vivo innate cytokine production is not predictive for rAd 
potency in vivo, and there is a broadly applicable inverse relation-
induction of optimal CD8 T cell responses to all rAds tested. This 
highlights a key commonality across rAds with regard to mecha-
nisms of Ag presentation and CD8 T cell priming.
In terms of innate signaling pathways, type I IFN-related 
genes were upregulated by many of the rAd vaccines in vivo, but 
the corresponding rAd-derived pathogen-associated molecular 
patterns (PAMPs) that trigger this pathway remain to be identiied. 
A number of candidate PAMPs have been suggested for adeno-
viruses, including virally associated RNAs (47), CpG motifs (48), 
and the adenoviral DNA itself (21). A key inding shown here was 
that STING acts as a PRR for all human rAds (rAd5, rAd28, and 
rAd35) and most notably chAd63. Indeed for rAd5 and chAd63, the 
IFN-driven gene expression proile was abrogated entirely in the 
absence of STING, leading us to hypothesize that STING acts as 
a proximal and dominant PRR after vaccination with certain rAds. 
STING likely senses rAd-derived DNA exposed as the viral parti-
cles uncoat in transfected cells (37, 38, 41–43). We speculate that 
accessibility of rAd-derived DNA to DNA sensors may difer due to 
diferent uncoating processes across adenoviral serotypes, leading 
to diferential ISG induction observed in our study. Once activated 
by way of an unidentiied DNA sensor, STING mediates phospho-
rylation of IRF3 to predominantly drive IFN production (49). Sig-
naling via TLR- and RLR-triggered pathways drives IFN produc-
tion through the action of IRFs but also drives proinlammatory 
cyto kine production through NF-κB activation, and these pathways 
augment CD8 T cell immunity after rAd vaccination (16, 18–20). 
The relative threshold and eiciency for driving IFN production 
and subsequent ISG activation across STING, RLR, and TLR path-
ways is not known. The impact of STING, RLR, and TLR signal-
ing may also difer across diferent cell types, due to diferential 
expression of each receptor and their downstream adaptors. While 
PRR signaling in the transfected cell is important, cells that phago-
cytose defective rAd particles may also sense PAMPs, and IFN 
production by a transfected cell leads to further production by sur-
rounding cells, which results in the overall antiviral response. Thus, 
the data presented here and from other studies show that innate 
immunity following rAd vaccination depends on the interplay of 
STING-, RLR-, TLR-, and possibly other PRR-mediated signaling 
pathways, in both hematopoietic and nonhematopoietic cells, both 
directly transfected by rAd and indirectly exposed. Remarkably, 
durable and functional CD8 T cell immunity appears independent 
of each of these intracellular innate signaling pathways in isola-
tion and suggests that redundancy and crosstalk is critical to PRR- 
mediated regulation of innate and adaptive immunity.
A broader inding of this study is that early type I IFN produc-
tion is not a general requirement for viral vector-induced CD8 T 
cell immunity. Prior studies have shown that type I IFN can sig-
nal CD8 T cells directly during the expansion phase to promote 
their survival in memory populations (50, 51). It is required for 
induction of CD8 T cell responses with certain infections, such as 
lymphocytic choriomeningitis virus (52, 53), and this efect was 
recently shown to be through type I IFN signaling to CD8 T cells in 
the early phases of proliferation, which prevents expression of the 
NCR1 receptor that would otherwise facilitate NK cell–mediated 
killing of these cells (54, 55). In contrast, infection-induced CD8 
T cell responses can be partially or entirely independent of type I 
IFN, such as with vesicular stomatitis virus, L. monocytogenes, and 
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Intracellular cytokine staining. Spleens were harvested and restim-
ulated as described previously (9), using the immunodominant SIV-
Gag peptides AL11 and DD13 (DRFYKSLRAEQTD) (65) restricted 
by MHC class I and class II, respectively (each at 2 μg/ml), or (b) 
full-length SIV-Gag protein (20 μg/ml). Samples were also incubated 
with anti-CD28 (clone 37.51; BD Pharmingen) and brefeldin A (BFA) 
alone to establish background cytokine production. BFA was withheld 
from samples undergoing protein stimulation for 2 hours to permit Ag 
processing. Cells were then stained with an ICS panel (LIVE/DEAD 
Fixable Violet Viability Dye; Life Technologies), anti–CD8-APC-
Cy7 (clone 53-6.7; BioLegend), anti–CD4-AF700 (clone RM4-5; BD 
Pharmingen), anti–CD3-PerCP-Cy5.5 (clone 145-2C11; BD Pharmin-
gen), anti–IFN-γ-APC (clone XMG1.2; BD Pharmingen), anti–IL-2-PE 
(clone JES6-5H4; BD Pharmingen), anti–TNF-APC-Cy7 (clone MP6-
XT22; BD Pharmingen), and anti–IL-10-AF488 (clone JES5-16E3; 
eBioscience) as described previously (9).
dLN DC and leukocyte subset staining. For DC subset identiication, 
both popliteal LNs were harvested and pooled from 10 mice for each 
EGFP-expressing rAd and processed and stained as described previ-
ously (22). Briely, DCs were isolated by enzymatic digestion of dLNs 
and enriched by CD11c+ positive selection according to the manufac-
turer’s instructions (Miltenyi Biotec). Cells were then stained with the 
DC panel (LIVE/DEAD Fixable AquaBlue Viability Dye (Life Technol-
ogies), B220-PE-Cy7 (clone RA3-6B2; BD Pharmingen), CD8-APC-
Cy7 (clone 53-6.7; Biolegend), CD11b-AF700 (clone M1/70; BioLeg-
end), pan-NK-Paciic Blue (clone DX5; BioLegend), CD19-Paciic Blue 
(clone 6D5; BioLegend), CD11c-PE (clone HL3; BD Pharmingen), 
CD103-PerCP-Cy5.5 (clone 2E7; BioLegend), CD3-PE-Cy5 (clone 
145-2C11; BD Pharmingen), Langerin-AF647 (clone 929F3.01; Den-
dritics), and DEC205-biotin (clone NLDC-145; Miltenyi Biotec), fol-
lowed by streptavidin-Texas Red-PE (BD Pharmingen). DC numbers 
were back calculated to represent cells per dLNs.
For leukocyte subset identiication, dLNs were processed as above 
and then stained with a LN subsetting panel (LIVE/DEAD Fixable 
AquaBlue Viability Dye; Life Technologies), CD8-APC-Cy7 (clone 
53-6.7; Biolegend), CD4-PerCP-Cy5.5 (clone RM4-5; BD Pharmin-
gen), CD19-APC (clone 6D5; BD Pharmingen), B220-PE-Cy7 (clone 
RA3-6B2; BD Pharmingen), CD11c-PE (clone HL3; BD Pharmingen), 
CD11b-AF700 (clone M1/70; BioLegend), pan-NK-Paciic Blue (clone 
DX5; BioLegend), CD3-PE-Cy5 (clone 145-2C11; BD Pharmingen), 
Gr1-FITC (clone RB6-8C5; eBioscience), and F4-80-Biotin (clone 
BM8; eBioscience), followed by streptavidin-Qdot-655 (Life Technol-
ogies). Leukocyte populations were calculated to represent the pro-
portion of the total dLN population.
Serum cytokine ELISAs. Cytokine was quantiied in serum after 
rAd vaccination using the Verikine Mouse IFN-α ELISA Kit (PBL Assay 
Science) or the Quantikine Mouse CXCL-10/IP-10/CRG-2 ELISA Kit 
(R&D Systems), according to the manufacturer’s instructions.
NK1.1+ cell depletion. To deplete NK cells, mice were administered 
100 μg NK1.1 antibody (clone PK136) intraperitoneally 2 days before 
vaccination and a further 25 μg the day after vaccination with rAd5 or 
rAd35. A control antibody (clone GL113, rat IgG) was given to a parallel 
group of mice. Efective depletion was checked the day before vaccina-
tion using the pan-NK antibody (clone DX5).
Flow cytometry. Samples were resuspended in 0.5% paraformal-
dehyde before acquisition using a modiied LSR II low cytometer (BD 
Biosciences). Results were analyzed using FlowJo version 9.3, Pestle 
ship between innate immunity and Ag expression across human-, 
chimpanzee-, and simian-derived rAds. The inding that chAd3 
and rAd5 induce comparable CD8 T cell immunity through similar 
innate mechanisms provides strong evidence that chAd3 may be an 
appropriate replacement for rAd5, which would be important for 
use in regions with high natural seroprevalence for rAd5. Indeed, 
chAd3 is now being tested for prevention of Ebola in Africa, based 
on nonhuman primate studies that show that rAd5 and chAd3 con-
fer a high level of protection (11, 62). Generation of a diverse collec-
tion of rAds for clinical use is important, as rAds are lead vaccine 
candidates for several infections and therapeutic tumor vaccines, 
but rAd administration induces Ad-speciic antibodies that can limit 
the eicacy of subsequent vaccination with a homologous serotype 
(63). Therefore, development of a serotypically diverse array of 
rAds with understanding of their mechanisms of action will be criti-
cal for optimizing rAd use in multiple vaccine strategies.
Methods
Mice. C57BL/6 WT, Batf3–/–, and STING gt/gt mice were obtained from 
The Jackson Laboratory. Ifnabr–/– mice were originally derived by Müller 
et al. (36). Mavs–/– mice were a gift from Zhijian Chen (University of Texas 
Southwestern, Dallas, Texas, USA) and were backcrossed to C57BL/6 
mice for 9 generations at Seattle BioMed. All mice used in the present 
experiments were housed at the Vaccine Research Center Biomedical 
Research Unit. Mice were 6 to 12 weeks old at the time of vaccination.
Vectors, vaccinations, and listerial infections. Vectors were grown 
and puriied as described previously (9). rAd5, rAd28, rAd35, sAd11, 
and sAd16 expressing SIV-Gag were obtained from GenVec Inc. chAd3 
and chAd63 backbones were obtained from Okairos Srl (6, 7). All rAds 
were rendered replication deicient through targeted deletion of the 
E1 adenoviral gene; the E3 gene was additionally deleted in chAd3 and 
chAd63, and both the E3 and E4 genes were additionally deleted in 
rAd5. The target transgene was inserted into the E1 locus for all con-
structs under the control of the CMV promoter. All vectors contained a 
codon-optimized version of Gag/Pol from SIV strain mac239 or EGFP. 
Poly I:C was formulated with poly-lysine and carboxymethylcellulose 
(64) to increase in vivo stability and used at a dose of 50 μg, given in 
the same inoculum as the rAd5.
Attenuated L. monocytogenes (ΔactA, ΔintB) expressing Gag from 
SIV strain mac239 was used for infectious challenge. L. monocytogenes 
expressing Gag was provided by ANZA Therapeutics and administered 
intravenously at a dose of 2 × 107 colony-forming units in a volume of 
300 μl. Spleens were processed as described previously (9) and back 
calculated to yield values for total colony-forming units per spleen.
Tetramer staining. Splenocytes or peripheral blood lymphocytes 
were harvested and stained with a tetramer panel (LIVE/DEAD Fix-
able Red Viability Dye; Life Technologies), anti–CD8-APC-Cy7 (clone 
53-6.7; BioLegend), anti–CD62L-PE-Cy7 (clone MEL-14; Abcam), 
anti–KLRG1-FITC (clone 2F1; Southern Biotech), anti–CD127-AF647 
(clone A7R34; eBioscience), and anti–CD3-PerCP-Cy5.5 (clone 
145-2C11; BD Pharmingen) after SIV-Gag AL11 tetramer labeling as 
described previously (9). Lung-derived lymphocytes were isolated 
by incubating dissected lung tissue in 5 ml RPMI containing DNase I 
(20 μg/ml; Roche) with collagenase type I (2.25 mg/ml; Life Technol-
ogies) for 30 minutes before agitation and washing. Red blood cells 
were then lysed using ACK lysis bufer (Lonza), and the remaining 
cells were washed before staining as above (9).
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ments, with all experiments repeated at least twice. A P value of 0.05 
was considered signiicant.
Statistical techniques used for microarray-derived data and correl-
ative analyses are described speciically in the Supplemental Methods.
Study approval. All experimental mouse protocols were approved 
by the Vaccine Research Center Animal Care and Use Committee, 
under ethics protocols VRC-08-220, VRC-10-314, and VRC-11-376.
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version 1.6.2, and SPICE version 5.22 software. Background cytokine 
staining was subtracted, based on control samples incubated with 
anti-CD28 and BFA in the absence of peptide or protein.
Microarrays and quantitative analysis of Ag expression. Draining 
popliteal lymph nodes were mechanically processed into single-cell 
suspensions in RNAlater (for Ag expression by qRT-PCR) (Invitro-
gen) or RNAprotect Cell Reagent (for mRNA analysis by microarray) 
(Qiagen). RNA was isolated using the RNAqueous 4PCR Kit (Ambion) 
as per the manufacturer’s instructions, and yield and quality was 
checked using the RNA6000 Chip on a 2100 Bioanalyzer (Agilent). 
Ag transcripts were quantiied via 1-step qRT-PCR using the iScript 
system (Ambion) as per the manufacturer’s instructions, with SIV-Gag 
mac239-speciic forward (5′-agagcctgctggagaacaag-3′) and reverse 
(5′-ctcggtgtgcttcaccttct-3′) primers and a FRET probe (5′-dFAM-tct-
ggtgcatccacgccgag-BHQ-3′) on a 7900HT Sequence Detection Sys-
tem (ABI Prism). Expression was measured against a standard curve 
of full-length SIV-Gag and calculated as the number of transcripts per 
whole dLN. RNA microarray analysis was conducted using the Agil-
ent SurePrint G3 Mouse GE 8 × 60K microarray platform as described 
previously (66). Labeling was performed using the One-Color Micro-
array-Based Gene Expression Analysis v.6.5 protocol (Agilent). Details 
regarding microarray data analysis are provided in the Supplemen-
tal Methods. All microarray data are publically available through the 
Gene Expression Omnibus (67) (accession no. GSE64548).
Statistics. Statistical signiicance for basic biological data was cal-
culated using a 2-tailed Mann-Whitney test using PRISM software. 
The Mann-Whitney test was chosen given the small number of repli-
cates with biological data that may not be parametrically distributed, 
and 2 individual groups were compared in each analysis. At least 3 
biological replicates are depicted in all igures, although we gener-
ally included 4–5 individual mice per treatment group for short-term 
(1–28 days) experiments and 5–6 mice per treatment group for longer- 
term (>28 days) studies, and 10 mice were pooled for DC experi-
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